CYB5B

Across TCGA pan-cancer cohorts, CYB5B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYB5B data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CYB5B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYB5B expression acts as an unfavorable survival marker.

LUAD, LSCC, and CCRCC are the cancer types where CYB5B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.283	0.717	.002	27	view →
LSCC	OS	Tertile	II,III,IV	0.593	0.915	.003	27	view →
CCRCC	DFS	Median	III,IV	0.427	0.762	.005	24	view →
HNSC	OS	Quartile	All	0.152	0.964	.017	12	view →
PDAC	DFS	Quartile	III,IV	0.577	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYB5B–LUAD (DFS)

Open the LUAD breakdown →